Related Experiment Videos
Risk of heart failure associated with dopamine agonists: a nested case-control study
1Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, 1 Jen-Ai Road, Section 1, Taipei, 10051, Taiwan.
Drugs & Aging
|July 25, 2013
Summary
Dopamine agonists, including pramipexole, showed a non-significantly increased risk of heart failure in Taiwanese patients. Further research is needed to confirm this association between dopamine agonist use and heart failure.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Pramipexole, a dopamine agonist, may increase heart failure risk in Caucasians.
- This association remains unexamined in Asian populations.
Purpose of the Study:
- To investigate the relationship between dopamine agonist use and heart failure risk in Taiwan.
- To explore the specific risks associated with pramipexole and other dopamine agonists.
Main Methods:
- A nested case-control study using Taiwan's National Health Insurance research database (NHIRD).
- 27,135 patients prescribed anti-parkinsonian drugs (2001-2010) were analyzed.
- 1,707 heart failure cases were matched with 3,414 controls using multivariable conditional logistic regressions.
Main Results:
- Current use of ergot-derived dopamine agonists was linked to increased heart failure risk (aOR 1.46).
- Non-ergot-derived dopamine agonists, including pramipexole and ropinirole, showed non-significantly increased heart failure risks.
- A trend suggested increased heart failure risk with longer pramipexole use, though statistical power was limited.
Conclusions:
- Dopamine agonist use, including pramipexole, was associated with a non-significantly increased risk of heart failure in Taiwan.
- Further investigation is required to elucidate the potential link between dopamine agonists and heart failure.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...